Impact of ileostomy creation on apixaban plasma concentrations: a retrospective case-series [PDF]
Annals of Saudi MedicineBACKGROUND: Apixaban is a direct-acting oral anticoagulant indicated for stroke and systemic embolism prevention in atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE).
Hakeam A. Hakeam +3 more
doaj +2 more sources
Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground The SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism) trial demonstrated the safety of apixaban for thromboprophylaxis in children with heart disease.
Ghada A. Aborkhees +14 more
doaj +2 more sources
Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
Frontiers in Veterinary Science, 2021 Thrombosis is common in critically ill dogs and causes considerable morbidity and mortality. The direct factor Xa inhibitor apixaban is safe, efficacious, and convenient in humans.
Noelle D. Herrera +5 more
doaj +1 more source
Hospital Pharmacy, 2013 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J +2 more
openaire +3 more sources
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. [PDF]
PLoS ONE, 2018 Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin.
Xiaoyan Li +11 more
doaj +1 more source
Scientific Reports, 2021 In some clinical situations, measurements of anticoagulant effect of apixaban may be needed. We investigated the inter- and intra-individual apixaban variability in patients with atrial fibrillation and correlated these results with clinical outcome.
Alenka Mavri +7 more
doaj +1 more source
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. [PDF]
PLoS ONE, 2012 BACKGROUND: Apixaban was shown to be superior to adjusted-dose warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke, and associated with reduced rates of ...
Soyon Lee +3 more
doaj +1 more source
PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST
Рациональная фармакотерапия в кардиологии, 2015 Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base of the efficacy in the prevention of ischemic stroke in patients with atrial fibrillation.
D. A. Sychev +6 more
doaj +3 more sources
Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
Frontiers in Cardiovascular Medicine, 2021 Background and Objectives: Real-world evidence of apixaban treatment in patients with chronic kidney disease remains scarce. This study aimed to compare the relative risk of stroke or systemic embolism (SE) and major bleeding between apixaban and ...
Chung-Ming Fu +6 more
doaj +1 more source
A study on indices of apixaban anticoagulation: A single-center prospective study
Journal of Pharmacological Sciences, 2018 Background: Depending on the characteristics of patients, the blood concentration of apixaban can unexpectedly increase, possibly leading to bleeding events.
Maki Komiyama +11 more
doaj +1 more source